Research Topics
| T M FileSummaryAffiliation: Summa Health System Country: USA Publications
| Collaborators
|
Detail Information
Publications
Solutions to the problem of bacterial resistanceThomas M File
Northeastern Ohio Universities College of Medicine, Akron, Ohio 44304, USA
Treat Respir Med 4:25-30. 2005....
Case studies of lower respiratory tract infections: community-acquired pneumoniaThomas M File
Department of Internal Medicine and Infectious Disease Section, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio, USA
Am J Med 123:S4-15. 2010..The cases presented in this review highlight many of the recent recommendations from the IDSA/ATS guidelines...- Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strainsThomas M File
Summa Health System, 75 Arch Street, Akron, OH 44304, USA
Int J Antimicrob Agents 25:110-9. 2005..Both amoxicillin/clavulanate, 2000/125 mg and comparators were well tolerated, with few patients withdrawing from the studies... - Antimicrobial therapy of community-acquired pneumoniaThomas M File
Summa Health System, 75 Arch Street, Suite 105, Akron, OH 44304, USA
Infect Dis Clin North Am 18:993-1016, xi. 2004.... - Lower respiratory tract infectionsThomas M File
Summa Health System, 75 Arch Street, Akron, OH 44304, USA
Infect Dis Clin North Am 18:xiii-xiv. 2004 - Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumoniaThomas M File
Department of Internal Medicine, Northeastern Ohio Universities, College of Medicine, Rootstown, Ohio, USA
Clin Infect Dis 39:S159-64. 2004.... 
Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of T M File
Summa Health System, Akron, OH 44304, USA
Antimicrob Agents Chemother 48:3323-31. 2004....- New insights in the treatment by levofloxacinThomas M File
Infectious Disease Service, Summa Health System, Akron, Ohio 44304, USA
Chemotherapy 50:22-8. 2004..Remarkably, levofloxacin continues to expand its list of indications. The development of a new high-dose 750-mg schedule has the potential to decrease the duration of treatment as well as reduce the emergence of resistance... - Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patternsThomas M File
Department of Internal Medicine, Northwestern Ohio Universities College of Medicine, Rootstown, OH, USA
Clin Lab Med 24:531-51. 2004..The b-lactamase inhibitor clavulanate allows for coverage of b-lactamase-producing pathogens, such as H influenzae and M catarrhalis. This article reviews the rationale for, and evolution of, oral amoxicillin clavulanate for ABRS and CAP.. - Guidelines for empiric antimicrobial prescribing in community-acquired pneumoniaThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, OH, USA
Chest 125:1888-901. 2004..Prospective data are required to evaluate which of these two approaches offers clinical superiority... - Telithromycin new product overviewThomas M File
Department of Medicine, College of Medicine, Northeastern Ohio University, Rootstown, OH, USA
J Allergy Clin Immunol 115:S1-13. 2005.... - Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumoniaThomas M File
Summa Health System, Akron, Ohio, USA; and Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Curr Opin Infect Dis 18:123-4. 2005 - Severe acute respiratory syndrome: pertinent clinical characteristics and therapyThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Treat Respir Med 4:95-106. 2005.... - Burden of community-acquired pneumonia in North American adultsThomas M File
Department of Internal Medicine, Northeastern Ohio University, College of Medicine, Rootstown, OH, USA
Postgrad Med 122:130-41. 2010..Given the significance of the disease burden, the potential benefit of pneumococcal vaccination in adults is substantial... - The science of selecting antimicrobials for community-acquired pneumonia (CAP)Thomas M File
Infectious Disease Section, Northeastern Ohio University College of Medicine, Rootstown, OH, USA
J Manag Care Pharm 15:S5-11. 2009..Initiating appropriate empiric therapy can be challenging given elevated resistance rates among Streptococcus pneumoniae strains... - What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumoniaThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Clin Infect Dis 47:S157-65. 2008..Because the composite rate of success in recent randomized clinical trials exceeds 90%, it would seem that a noninferiority margin of 10% is reasonable for trials for mild CAP... - The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adultsThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, OH Infectious Disease Service, Summa Health System, Akron, OH, USA
Int J Antimicrob Agents 30:S131-4. 2007.... - Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital settingThomas M File
Northeastern Ohio Universities College of Medicine, Akron, OH 44304, USA
Cleve Clin J Med 74:S6-11. 2007..This article provides a brief review of the differences between health care-associated and community-acquired MRSA and discusses the potential impact of the changing epidemiology of MRSA on the hospital setting... - Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind studyThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, OH and Summa Health System, 75 Arch Street, Suite 105, Akron, OH 44304, USA
J Antimicrob Chemother 60:112-20. 2007..Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP... - Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelinesThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, and Summa Health System, Akron, Ohio, USA
Clin Infect Dis 51:S42-7. 2010..Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator... - Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumoniaT M File
Summa Health System, Akron, Ohio 44304, and North eastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Clin Microbiol Infect 12:31-41. 2006..Continued surveillance studies, appropriate antimicrobial usage campaigns, stratification of patients based on known risk factors for resistance, and vaccination programmes are needed to appropriately manage DRSP and limit its spread... - Community-acquired pneumoniaThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, and Infectious Disease Service, Summa Health System, Akron, Ohio, USA
Lancet 362:1991-2001. 2003..The appropriate use of vaccines against pneumococcal disease and influenza should be encouraged. Several guidelines for management of CAP have recently been published, the recommendations of which are reviewed... - Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimensT M File
Department of Internal Medicine, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Chemotherapy 47:11-8; discussion 26-7. 2001..A systematic therapeutic approach including a microbiological evaluation to identify the causative pathogen and its susceptibility will help to ensure that an appropriate antimicrobial agent is used... - Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanateThomas M File
Summa Health System, Northeastern Ohio Universities College of Medicine, 75 Arch Street, Suite 105, Akron, OH 44304, USA
Int J Antimicrob Agents 20:235-47. 2002..pneumoniae infection as this formulation covers many PRSP that are non-susceptible to amoxycillin (+/-clavulanic acid) (MICs of >/=4 mg/l) as well as common beta-lactamase-producing respiratory pathogens... - Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumoniaT M File
Northeastern Ohio Universities College of Medicine, Rootstown, USA
Clin Infect Dis 29:426-8. 1999..The presence of comorbid illnesses and the requirement of supplemental oxygen therapy were the most common criteria for hospital admission... - Rational use of antibiotics to treat respiratory tract infectionsThomas M File
Department of Medicine, Summa Health System, Akron, OH, USA
Am J Manag Care 8:713-27. 2002..To foster the appropriate use of antimicrobial agents for respiratory tract infections and to review factors that should help achieve this objective... - The epidemiology of respiratory tract infectionsT M File
Department of Internal Medicine, Northeastern Ohio Universities College of Medicine, Rootstown, USA
Semin Respir Infect 15:184-94. 2000..pneumoniae) has also increased the challenge for appropriate management of RTI. An awareness of the epidemiology and cause of specific respiratory infections should optimize care... - Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacinT M File
Summa Health System, Akron Infectious Diseases Inc, OH 44304, USA
J Antimicrob Chemother 48:67-74. 2001..Gemifloxacin was well tolerated and the incidence of transient liver function abnormalities was very low. Gemifloxacin is an effective and well-tolerated treatment for patients with CAP... - Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniaeThomas M File Jr
Department of Internal Medicine, Northeastern Ohio Universities College of Medicine, Rootstown, and Infectious Disease Service, Summa Health System, Akron, OH, USA
Clin Infect Dis 34:S17-26. 2002..The clinical relevance of in vitro resistance may be related to at least 3 factors: concordance of antimicrobial therapy, severity of illness, and virulence... - International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolidesThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Drugs 63:181-205. 2003..The difference in the emphasis placed on the importance of the atypical pathogens as well as the expression of MRSP in North America compared with Europe partly explains this variance... - Streptococcus pneumoniae and community-acquired pneumonia: a cause for concernThomas M File
Infectious Disease Service, Summa Health System, Akron, Ohio, USA
Am J Med 117:39S-50S. 2004.... - A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibioticThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, OH, USA
Int J Antimicrob Agents 33:58-64. 2009..For S. pneumoniae, achieving an AUIC > or =100 can attenuate progression, regardless of GLG. Thus, AUIC > or = 100 appears to be a viable antibiotic selection strategy to protect patients with S. pneumoniae from developing CAP... - Clinical and public health implications of macrolide-resistant Streptococcus pneumoniaeR C Moellering
Beth Israel Deaconess Medical Center, Department of Medicine, Boston, MA 02215, USA
J Chemother 14:42-56. 2002..Further studies are required to monitor and control macrolide resistance and evaluate settings in which macrolide treatment failures are occurring, and new therapeutic interventions are needed... - Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infectionsThomas M File
Northeastern Ohio Universities, College of Medicine and Summa Health System, 75 Arch St Suite 105, Akron, OH 44304, USA
Expert Rev Anti Infect Ther 2:831-43. 2004..2%. A nonphototoxic rash (usually a mild, maculopapular rash) was observed in 2.8% of patients in clinical studies... - Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumoniaKevin B Anderson
Summa Health System, Akron, Ohio 44304, USA
Clin Infect Dis 37:376-81. 2003..In immunocompromised patients with suspected or proven pneumococcal infection, it may be prudent not to use fluoroquinolone monotherapy empirically when the patient has a history of fluoroquinolone therapy in at least the past 4 months... - The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study GroupM J Tan
Departments of Internal Medicine, Summa Health System, Akron, OH, USA
Chest 117:398-403. 2000..To study the serial radiographic manifestations of Legionnaire's disease from the initial presentation on admission to recovery using strict criteria for the diagnosis of infection... - Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophilaJ S Tan
Summa Health System and Northeastern Ohio Universities College of Medicine, Akron, OH 44304, USA
Clin Infect Dis 32:1562-6. 2001..The poor outcome may have been partially due to the suspected underlying lung malignancy, as shown by cytologic examination, and by a delay in seeking medical attention... - [Clinical impact of appropriate use of antibiotic in hospital according to CARAT criteria]Thomas M File
Infectious Disease Section, Department of Internal Medicine, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
Infez Med 16:30-7. 2008..Promoting the appropriate use of antibiotics should provide for optimal outcomes for our patients... - Overview of resistance in the 1990sT M File
Northeastern Ohio Universities, College of Medicine, Rootstown, USA
Chest 115:3S-8S. 1999..Responsible antibiotic use and stringent infection-control policies are needed to discourage the development of resistant strains... - Levofloxacin in the treatment of community acquired pneumoniaT M File
Infectious Disease Section, Summa Health System, Akron, Ohio, USA
Can Respir J 6:35A-9A. 1999.... - Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory settingJames S Tan
Infectious Disease Section, Department of Internal Medicine, Northeastern Ohio Universities College of Medicine and Summa Health System, Akron, Ohio 44304, USA
Am J Respir Med 2:385-94. 2003..Following prompt intravenous therapy and stabilization, patients with CAP should be treated with oral therapy in the ambulatory setting... - How long should we treat community-acquired pneumonia?Nikole M Scalera
Summa Health System, Akron, Ohio 44304, USA
Curr Opin Infect Dis 20:177-81. 2007.... - Legionnaires disease with bacteremic coinfectionMichael J Tan
Department of Internal Medicine, Summa Health System, Akron, OH, USA
Clin Infect Dis 35:533-9. 2002..Initial empiric antimicrobial therapy for patients who live in areas of endemicity and who are smokers should be treated with antimicrobial agents that have activity against pneumococcus and Legionella species... - Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaThomas M File
Northeastern Ohio Universities College of Medicine, Rootstown, OH, USA
Curr Med Res Opin 20:1473-81. 2004..Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen... - A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumoniaThomas M File
Northeastern Ohio University College of Medicine, Rootstown, Ohio, USA
Clin Cornerstone . 2003..This article discusses the use of high-dose, short-course fluoroquinolone therapy as an effective option for patients with community-acquired pneumonia... - Ventilator-associated pneumonia: gearing towards shorter-course therapyThea de Jesus Chua
Summa Health System, 75 Arch Street, Akron, OH 44304, USA
Curr Opin Infect Dis 19:185-8. 2006..SUMMARY: The minimum effective duration of antibiotic therapy, however, remains unclear. Further studies geared towards determining this are needed... - Performance measure of urinary antigen in patients with Streptococcus pneumoniae bacteremiaJohn Selickman
Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Diagn Microbiol Infect Dis 67:129-33. 2010..03). Test performance was less sensitive than prospective studies indicate. Patients with impaired renal function were significantly more likely to have positive UAg tests... - Performance measurement in community-acquired pneumonia: consequences intended and unintendedThomas M File
Clin Infect Dis 44:942-4. 2007 - A worldwide perspective of atypical pathogens in community-acquired pneumoniaForest W Arnold
Division of Infectious Diseases, University of Louisville, Louisville, KY 40292, USA
Am J Respir Crit Care Med 175:1086-93. 2007..In different regions of the world, monotherapy with a beta-lactam antimicrobial is common... - Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremiaMark I Neuman
Division of Emergency Medicine, Children s Hospital, Boston, Massachusetts 02115, USA
J Emerg Med 32:349-57. 2007..7). Harboring an antibiotic non-susceptible strain (OR 1.4) and male sex (OR 1.4) were associated with increased risk of mortality, whereas black race (OR 0.6) and evidence of focal infection (OR 0.6) were associated with decreased risk... - Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumoniaCristina Tanaseanu
Department of Internal Medicine, St Pantelimon Clinical Emergency Hospital, Bucharest OP 22, Romania
Diagn Microbiol Infect Dis 61:329-38. 2008..6% TGC versus 6.9% LEV) were significantly higher in LEV. Discontinuations for AEs were low (TGC, 26 patients [6.1%]; LEV, 34 patients [8.1%]). TGC appeared safe and achieved cure rates similar to LEV in hospitalized patients with CAP... - Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsLionel A Mandell
McMaster University Medical School, Hamilton, Ontario, Canada
Clin Infect Dis 44:S27-72. 2007 - Levofloxacin for the treatment of community-acquired pneumoniaJoseph P Lynch
University of California, Los Angeles, Division of Pulmonary, Critical Care Medicine and Hospitalists, The David Geffen School of Medicine, Los Angeles, CA, USA
Expert Rev Anti Infect Ther 4:725-42. 2006..However, ciprofloxacin-resistant organisms are becoming more prevalent so prudence must be exercised when prescribing this agent... - Short-course treatment of community-acquired pneumoniaLionel A Mandell
Clin Infect Dis 37:761-3. 2003 - Shorter course therapy of serious respiratory infections: new data for new approaches to managementThomas M File
Curr Opin Infect Dis 17:105-7. 2004 - Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficHartmut Lode
Department of Chest and Infectious Diseases, Hospital Heckeshorn, Akademisches Lehrkrankenhaus, Free University Berlin, Berlin, Germany
Clin Ther 24:1915-36. 2002.... - What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?Thomas M File
Clin Infect Dis 36:396-8. 2003 - Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problemSanjay Sethi
Division of Pulmonary and Critical Care Medicine, State University of New York, VA Medical Research, Buffalo, NY, USA
Curr Med Res Opin 20:1511-21. 2004..There is a substantial need for more research to understand the etiology and identify efficacious interventions to reduce the frequency of exacerbations of COPD... - Etiology and management of community-acquired pneumonia in AsiaToshiharu Matsushima
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
Curr Opin Infect Dis 15:157-62. 2002..pneumoniae. Some Asian countries have their own guidelines for community-acquired pneumonia, but these are written in their own languages... - Judicious use of antibiotics to treat respiratory tract infectionsThomas M File
Curr Opin Infect Dis 15:149-50. 2002 - A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteriaThomas G Slama
Department of Infectious Diseases, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA
Am J Med 118:1S-6S. 2005..The criteria, which are aimed at optimizing antibiotic therapy, include evidence-based results, therapeutic benefits, safety, optimal drug for the optimal duration, and cost-effectiveness... - Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illnessThomas M File
Clin Infect Dis 41:1706-8. 2005 - Pneumonia in older adults: reversing the trendThomas M File
JAMA 294:2760-3. 2005 - The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspectiveThomas M File
Clin Infect Dis 42:798-800. 2006 - Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US StudyDavid J Farrell
G R Micro Ltd, 7 9 William Rd, London NW1 3ER, United Kingdom
J Clin Microbiol 45:290-3. 2007..However, the ketolide antibacterial telithromycin consistently demonstrated in vitro activity against these isolates over the 4 years of the study (MIC90=0.5 to 1 microg/ml)... - Medication options for the treatment of CAPLionel A Mandell
Am Fam Physician 74:1479. 2006 - Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adultsLionel A Mandell
McMaster University, Hamilton, Ontario, Canada
Clin Infect Dis 37:1405-33. 2003 - Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative studyTimothy C Fabian
University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
Surg Infect (Larchmt) 6:269-82. 2005..Meropenem, a broad-spectrum carbapenem with potent in vitro activity, is postulated to be an effective monotherapy for the treatment of complicated skin and skin structure infections (cSSSI)... - Viral respiratory tract infections: increasing importance and a new pathogenThomas M File
Curr Opin Infect Dis 16:125-7. 2003